Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Amicus Therapeutics Inc.
Headquarters: Cranbury, NJ, United States of America
Website: http://www.amicusrx.com/
Year Founded: 2002
Status: Public
Industry Sector: HealthTechnology
CEO: Bradley Lewis Campbell, MBA
Number Of Employees: 499
Enterprise Value: $3,060,962,329
PE Ratio: -37.38
Exchange/Ticker 1: NASDAQ:FOLD
Exchange/Ticker 2: N/A
Latest Market Cap: $2,116,883,584
BioCentury | Jan 15, 2025
Management Tracks
Auspitz becomes managing partner at Curie.bio
Plus: Amphista names Paul Medeiro CBO, and updates from Apellis, Forbion, Eqt, Egle, Spero, Molecular Templates and more
BioCentury | Aug 7, 2024
Product Development
Jim Wilson’s move to industry is anchored in global vision for ultrarare diseases
Gene therapy pioneer tells BioCentury his plans for his newcos GemmaBio and Franklin Biolabs
BioCentury | May 20, 2024
Politics, Policy & Law
BIO reorganizing, reimagining to increase impact
CEO Crowley is laying off 30 out of 160 staff, promoting some long-term employees, and seeking to revamp communications, enhance focus on patients
BioCentury | Apr 4, 2024
Politics, Policy & Law
BIO’s Crowley explains position on Biosecure Act, efforts to ease impacts
Biotechnology Innovation Organization CEO believes ‘thoughtful, systemic decoupling’ necessary to end U.S. reliance on Chinese biotechs
BioCentury | Mar 20, 2024
Product Development
Non-profit biotech aims to revive stalled ultrarare therapies
Orphan Therapeutics Accelerator will pursue hybrid non-profit, commercial model
BioCentury | Mar 15, 2024
Politics, Policy & Law
Crowley comes to Washington
BIO’s new CEO lays out his vision for the trade organization, putting patients center stage
BioCentury | Mar 13, 2024
Politics, Policy & Law
BIO reverses stance on Biosecure Act, pushes WuXi AppTec out
Trade group parting ways with China CDMO, plans to work with Biosecure sponsors to avoid supply chain disruptions
BioCentury | Feb 29, 2024
Regulation
Ultrarare inflection point: stakeholders argue for biomarker-based approvals
Reagan-Udall Foundation meeting on biomarkers could change FDA policy on neuronal MPS endpoints, unleash approvals
BioCentury | Feb 8, 2024
Politics, Policy & Law
Anti-China biotech bills raise alarms at U.S. biotechs
U.S. CEOs worried they could lose access to CDMOs WuXi AppTec and WuXi Biologics
BioCentury | Dec 15, 2023
Editor's Commentary
Biotech’s public policy pillars are crumbling
The U.S. preeminence in life sciences at risk
Items per page:
1 - 10 of 300